Connect with us

Business insider

The Mullings Group Appoints Rick Geoffrion as Vice Chairman

DELRAY BEACH, Fla., Jan. 13, 2021 /PRNewswire/ — Medical device executive Rick Geoffrion has been appointed as Vice Chairman of The Mullings Grou…

Published

on

DELRAY BEACH, Fla., Jan. 13, 2021 /PRNewswire/ — Medical device executive Rick Geoffrion has been appointed as Vice Chairman of The Mullings Group (TMG) Companies, a global leader in medtech talent acquisition and branding. Currently the Founder, President and CEO of Cyrano Therapeutics, Geoffrion also serves on the Executive Committee and the Board of Directors for the Medical Device Innovation Consortium. Geoffrion will report to Joe Mullings, Chairman and CEO of TMG Companies.

The Mullings Group (PRNewsfoto/The Mullings Group)

In his new role, Geoffrion will provide oversight over TMG’s brands including TMG Search, TMG360 Media and Dragonfly Stories, which provide talent acquisition services and corporate branding for emerging tech, medtech and healthtech companies. As well, he will leverage his experience on behalf of client partners as an emerging technology CEO in the medtech market, having brought companies and products including Impella, Pathway, Circulite, Mitralign and PercuSurge to the industry, as well as Cyrano Therapeutics, a biopharma company that he has recently established and funded.

“Over the last five years, Joe and his organizations have been ahead of the curve, executing on a mission to link professional media and corporate advisory with his well-established talent access business. As a result, his pioneering group of companies have been growing 30 percent year-over year in the midst of a challenging business environment. I am excited to help him fully realize this vision by lending a complementary perspective from the emerging medtech CEO chair,” said Geoffrion.

Founded in 1992, TMG built its reputation and business by partnering with emerging technology companies in the medtech field, building multi-functional teams to shepherd the client from inception to commercialization. Today, TMG is a tight-knit group of companies that not only help build multi-functional teams and companies, but also work with clients to build digital media strategies to establish branding and messaging to the community at large.

“Rick’s track record and understanding of the challenges that early-to-late-stage medtech CEO’s face in the industry is invaluable. His expertise and insight translates directly to our client partners as we enter into the golden age of medtech-healthtech and the need to build their teams, technologies and brands in this rapidly evolving industry,” said Mullings.

About The Mullings Group

Based in Delray Beach, Florida, The Mullings Group (TMG), since 1992, has grown to dominate the healthtech landscape in the field of talent acquisition. In the medtech field, TMG has completed more successful talent assignments than any other firm and over the last five years, have applied that successful model to the broader healthtech segment. TMG is best known for its innovative approach to digital media strategy and branding, including its proprietary Precruiting® and Digital Storytelling programs. More: https://mullingsgroup.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-mullings-group-appoints-rick-geoffrion-as-vice-chairman-301207050.html

SOURCE The Mullings Group Companies

Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post.

Source: https://markets.businessinsider.com/news/stocks/the-mullings-group-appoints-rick-geoffrion-as-vice-chairman-1029963804

Business insider

Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy

WUHAN, China and NEWARK, DE., Jan. 19, 2021 /PRNewswire/ — Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene …

Published

on

WUHAN, China and NEWARK, DE., Jan. 19, 2021 /PRNewswire/ — Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy company (hereafter Neurophth), and AAVnerGene Inc., a specializing AAV technology company, today announced a strategic partnership to provide Neurophth with worldwide rights to mutually select adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy.

AAVnerGene’s Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening platform can efficiently select the best AAV vector for each cell type in a high-throughput (HTP) manner. Major challenges in AAV-based gene therapy are the transduction efficiency, possible immunity to the capsid and complex manufacturing processes. The ability to identify suitable next generation AAV vectors that could overcome the limitations of earlier generation AAV vectors is critical to a patient for achieving sufficient therapeutic expression of the transferred gene in the lowest dose through common procedure such as intravitreal (IVT) injection with reasonable cost.

“AAVnerGene’s proprietary technology may create capsid libraries derived from artificial intelligence machine learning, DNA shuffling or directed evolution allowing a significant increase in AAV genetic payload capacity, production, and transduction with the ability to penetrate through the inner limiting membrane of the retina, thus potentially enhance the overall transduction efficiency of capsid library-derived AAV vectors,” said Alvin Luk, Ph.D., M.B.A., Chief Executive Officer of Neurophth. “Importantly, if proven successful, the administration of the selected AAVnerGene capsid variant(s) in gene therapy may enable repeated dosing AAVs in both adults and pediatric patients, potentially improving the clinical efficacy at a lower vector dose with better penetration of the barriers in eyes using a safer and less invasive procedure such as intravitreal injection which lower the risk of immune response to the capsid.”

“AAV is the most widely-used vector in gene therapy, however, its efficacy and cost will need significant improvement. Suitable AAV plays a vital role to achieve the success of a gene therapy. Our ATHENA platform is designed to select the optimal AAV vector for different cells and diseases,” said Daozhan Yu, Ph.D., Chief Executive Officer of AAVnerGene. “We are proud to partner with Neurophth, a recognized gene therapy leader, to accelerate the application of our AAV capsid libraries in gene therapy. Both parties aim to build a strategic partnership for long term success which will bring accessible AAV gene therapy treatment to patients around the world.”

Subject to the terms of the agreement, Neurophth will make an initial cash payment to AAVnerGene to test ~100 AAV capsids. Within 6-12 months upon receiving the AAV capsids, Neurophth is responsible for completing the preclinical studies on these capsids. Thereafter, both companies will jointly evaluate the capsids and selected the appropriate ones for further development. Upon the selection of the appropriate capsids, Neurophth has agreed to pay AAVnerGene additional cash and/or to potentially purchase AAVnerGene’s common stock being based on Neurophth’s achievement of specified development, regulatory and commercial milestones. In addition, Neurophth will pay AAVnerGene royalties for the sales of any resulting commercialized gene therapy.

The terms of this agreement do not apply to Neurophth’s ongoing investigational development programs in Leber hereditary optic neuropathy (LHON), including NR082 (NFS-01 program) for the treatment of ND4-mutated LHON and ND1-mutated LHON. This agreement does not impact Neurophth Therapeutics’ ongoing research in glaucoma, wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

About Neurophth

Neurophth is China’s first gene therapy company in ophthalmic diseases. Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and US, Neurophth, a fully integrated company, is striving to discover and develop gene therapies for patients suffering from blindness and other eye diseases globally. Our AAV validated platform which has been published in Nature – Scientific Reports, Ophthalmology, and EBioMedicine, successfully delivered proof-of-concept data with investigational gene therapies in the retina. Our most advanced investigational candidate, NR082 (rAAV2-ND4), in development for the treatment of ND4-mutated LHON, has received orphan drug designations in the U.S. The pipeline also includes ND1-mutated LHON, autosomal dominant optic atrophy, glaucoma, wAMD/DME, and other preclinical candidates. Neurophth has initiated the scaling up in-house process in single-use manufacturing technologies to support future commercial demand at the Suzhou facility. To learn more about us and our growing pipeline, visit www.neurophth.com.

About AAVnerGene

AAVnerGene Inc. is an innovative company leveraging AAV technologies to improve patients’ lives through the potential of gene therapy. With over 20 years of frontline gene therapy expertise, the company develops novel AAV vectors, methods and strategies that can efficiently produce, deliver and express high quality vectors into specific cells. The company’s goal is to utilize these vectors from ATHENA screening platform to enable the development of single administration of AAV gene therapy with higher expression, increased durability, reduced side effect and improved manufacturability, making it accessible to patients globally. For more information, please visit www.AAVnerGene.com.

Neurophth Therapeutics Contact:
PR@neurophth.com

AAVnerGene Contact:
customer@aavnergene.com

Cision View original content:https://www.prnewswire.com/news-releases/neurophth-and-aavnergene-enter-strategic-aav-capsids-partnership-for-next-generation-ophthalmic-gene-therapy-301210596.html

SOURCE Neurophth Therapeutics, Inc.

Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post.

Source: https://markets.businessinsider.com/news/stocks/neurophth-and-aavnergene-enter-strategic-aav-capsids-partnership-for-next-generation-ophthalmic-gene-therapy-1029979202

Continue Reading

Business insider

Spain Consumer Prices Fall As Estimated

(RTTNews) – Spain’s consumer prices continued to decline in December, as initially estimated, final data published by the statistical office INE s…

Published

on

(RTTNews) – Spain’s consumer prices continued to decline in December, as initially estimated, final data published by the statistical office INE showed on Friday.

The consumer price index decreased 0.5 percent year-on-year in December, following a 0.8 percent fall in November, as estimated.

The core inflation was 0.1 percent in December.

On a month-on-month basis, consumer prices rose 0.2 percent in December, same as seen in the previous month, as initially estimated.

On a monthly basis, the EU measure of harmonized index of consumer prices rose 0.2 percent in December versus a 0.1 percent growth in the initial estimate.

On an annual basis, the HICP fell 0.6 percent in December, following a 0.8 percent in the prior month, as estimated.

On a month-on-month basis, consumer prices rose 0.2 percent in December, same as seen in the previous month, as initially estimated.

Source: https://markets.businessinsider.com/news/interestrates/spain-consumer-prices-fall-as-estimated-1029972100

Continue Reading

Business insider

ATSG, Air Canada Agree To Sale, Conversion & Leaseback Of Two Boeing 767 Aircraft

(RTTNews) – Air Transport Services Group Inc. (ATSG) said that its Cargo Aircraft Management subsidiary has agreed to buy two Boeing 767-300ER air…

Published

on

(RTTNews) – Air Transport Services Group Inc. (ATSG) said that its Cargo Aircraft Management subsidiary has agreed to buy two Boeing 767-300ER aircraft from Air Canada of Montreal, convert them from passenger to freighter configuration, and lease them back to Air Canada.

ATSG noted that the first aircraft will be inducted for conversion in March 2021. Both are expected to be redelivered to Air Canada by the end of 2021.

In November 2020, Air Canada announced its strategic plan to use converted freighters to grow its cargo business across the global supply chain in response to evolving opportunities in the air freight market.

Source: https://markets.businessinsider.com/news/stocks/atsg-air-canada-agree-to-sale-conversion-leaseback-of-two-boeing-767-aircraft-1029968555

Continue Reading

Trending